Because available studies indicated that isocitrate dehydrogenase 1 (IDH1) mutants showed better prognosis compared to IDH-wildtype glioma patients at different WHO grades [25], therefore in the next step we analyzed proteasome activity depending on the mutation of the IDH1 gene. The gene discussed is IDH1; the disease is glioma.